

## PHYSIOLOGY

# Effect of Selective Blockade of $\alpha_{2C}$ -Adrenoceptors on Cardiac Activity in Growing Rats

T. L. Zefirov, L. I. Khisamieva, N. I. Ziyatdinova, and A. L. Zefirov\*

Translated from *Byulleten' Eksperimental'noi Biologii i Meditsiny*, Vol. 159, No. 6, pp. 664-666, June, 2015  
Original article submitted March 23, 2015

Selective blockade of  $\alpha_{2C}$ -adrenoceptors had different effects on the cardiovascular system in rats of various age groups. Blockade of  $\alpha_{2C}$ -adrenoceptors in adult rats and 3-week-old animals produced the positive and negative chronotropic effects, respectively. HR in 1-week-old and 6-week-old rats did not change during  $\alpha_{2C}$ -adrenoceptor blockade. Selective blockade of  $\alpha_{2C}$ -adrenoceptors in adult rats and 3-week-old animals was followed by the increase in BP. BP in 6-week-old rats was shown to decrease under these conditions.

**Key Words:** cardiovascular system; chronotropism;  $\alpha$ -adrenoceptors; rat

$\alpha_2$ -Adrenergic receptors ( $\alpha_2$ -AR) are involved in the regulation of various physiological systems [7]. Molecular and genetic studies revealed the following three subtypes of  $\alpha_2$ -AR:  $\alpha_{2A}$ -AR ( $\alpha_{2D}$ -AR in the rat),  $\alpha_{2B}$ -AR, and  $\alpha_{2C}$ -AR [5,6,9]. It was previously hypothesized that presynaptic  $\alpha_2$ -AR in the mammalian heart inhibiting the release of norepinephrine only modulate the regulatory influences. Recent studies showed that  $\alpha_2$ -AR are present in vascular smooth muscles, on presynaptic membranes of adrenergic fibers, and on postsynaptic membranes of cardiomyocytes [8,11,13]. Age-related differences in the chronotropic response to  $\alpha_2$ -AR blockade were revealed [1,2]. The dominating role of  $\alpha_{2A}$ -AR in the regulation of the cardiovascular system was demonstrated in experiments with  $\alpha_{2A}$ -AR gene knockout followed by HR increase [4]. The release of norepinephrine from the sympathetic nerve endings of the heart is regulated by presynaptic  $\alpha_{2A}$ -AR and  $\alpha_{2C}$ -AR [12], while knockout of these AR subtypes is followed by cardiac hypertrophy and heart

failure due to chronic stimulation of norepinephrine release in the heart and increase in epinephrine secretion from the adrenal glands [3,10]. As differentiated from  $\alpha_{2A}$ -AR and  $\alpha_{2C}$ -AR, most  $\alpha_{2B}$ -AR are located postsynaptically [12].  $\alpha_{2B}$ -AR are probably involved in the pathogenesis of acute coronary diseases [4]. Stimulation and blockade of  $\alpha_2$ -AR were shown to produce a potent cardiovascular effect in adult rats [2,15].


This work was designed to study the age-dependent effect of selective  $\alpha_{2C}$ -AR blockade on chronotropism and BP in rats during early postnatal ontogeny.

### MATERIALS AND METHODS

Experiments were performed on 30 outbred rats aging 1, 3, 6, and 20 weeks. Adrenergic regulation of the heart is absent in 1-week-old rats, and only develops in 3-week-old animals. The development of sympathetic regulation of the heart is completed by the age of 6 weeks; 20-week-old rats are considered adult.

The rats were intraperitoneally narcotized with 25% urethane in a dose of 800 mg/kg. A selective  $\alpha_{2C}$ -AR antagonist JP-1302 (Tocris) in a dose of 0.3 mg/kg was injected into the right femoral vein. ECG was continuously monitored and analyzed with a computer

Department of Anatomy, Physiology, and Human Health Protection,  
\*Department of Normal Physiology, Kazan State Medical University,  
Kazan, Republic of Tatarstan, Russia. **Address for correspondence:**  
zefirovt@mail.ru. T. L. Zefirov



**Fig. 1.** Effect of  $\alpha_{2c}$ -AR blockade on HR in rats. Ordinate: R-R interval. Arrow: recording of Xm immediately after antagonist injection. Here and in Fig. 2: \* $p<0.05$  and \*\* $p<0.01$  in comparison with the baseline (before treatment).

system. BP was measured using a SDK-1 device for noninvasive systolic pressure measurement. The data were transmitted to a computer and analyzed by L-Graf software.


The results were analyzed statistically. The significance of differences was evaluated by Student's test and Wilcoxon's tests (Microsoft Excel software).

## RESULTS

The mean R-R interval (Xm) decreased by  $6.0\pm1.4\%$  (from  $190.0\pm12.4$  to  $179.0\pm1.2$  msec;  $p<0.01$ ) on the 5th minute after *in vivo* administration of an  $\alpha_{2c}$ -AR antagonist JP-1302. By the 20th minute, Xm was shown to decrease by  $12.0\pm2.1\%$  ( $p<0.01$ ). Xm decreased progressively in the follow-up period and was minimum by the 60th minute after antagonist injection (Fig. 1). Xm in 6-week-old rats increased insignificantly by the 10th minute of the study (by  $5.0\pm5.2\%$ ; from  $143.0\pm8.3$  to  $149.0\pm7.4$ ). Xm was reduced 20 min after antagonist injection. However, the decrease in

HR under these conditions was also statistically insignificant. Xm in 3-week-old rats increased by  $8.0\pm2.8\%$  ( $p<0.05$ ) 5 min after antagonist injection. Xm progressively increased over 15 min after treatment, but decreased on the 60th minute of the study ( $p<0.01$ ; Fig. 1).  $\alpha_{2c}$ -AR blockade had no effect on Xm in 1-week-old rats (Fig. 1). Systolic BP in adult rats was shown to increase by  $4.0\pm1.5\%$  (from  $101.0\pm9.8$  to  $106.0\pm9.9$  mm Hg;  $p<0.05$ ) 5 min after  $\alpha_{2c}$ -AR blockade. The increase in BP was most significant 15 min after treatment ( $p<0.05$ ; Fig. 2). BP in 6-week-old rats decreased by  $8.0\pm2.1\%$  after 5 min ( $p<0.05$ ). BP in these animals was reduced by  $87.0\pm3.1\%$  on the 50th minute after treatment ( $p<0.01$ ). Systolic BP in 3-week-old rat pups was elevated immediately after antagonist injection ( $p<0.05$ ). BP increased most significantly by the 20th minute after treatment ( $p<0.01$ ) and remained unchanged in the follow-up period (Fig. 2).

Our study revealed the age-dependent effect of selective  $\alpha_{2c}$ -AR blockade on the cardiovascular system. Selective blockade of  $\alpha_{2c}$ -AR in adult animals was



**Fig. 2.** Effect of  $\alpha_{2c}$ -AR blockade on systolic BP in rats.

followed by the increase in HR and BP. Three-week-old rats were characterized by the decrease in HR and increase in BP. It should be emphasized that selective blockade of  $\alpha_{2C}$ -AR had no chronotropic effect in newborn and 6-week-old animals. BP was shown to decrease in 6-week-old rats.  $\alpha_2$ -AR are coupled to inhibitory Gi and Go proteins and decrease the activity of adenylate cyclase. At the same time,  $\alpha_2$ -AR can bind to Gs proteins and increase adenylate cyclase activity [8]. Selective blockade of various subtypes of  $\alpha_2$ -AR produces various effects, which is probably related to different localization of these receptors. We showed that  $\alpha_{2C}$ -AR blockade has the opposite effect on chronotropic activity of the heart and systolic BP in rats, which depends on the maturity of cardiac sympathetic regulation.

This work was supported by the Russian Foundation for Basic Research (grant No. 15-04-05384).

## REFERENCES

1. T. L. Zefirov, N. I. Ziyatdinova, L. I. Khisamieva, and A. L. Zefirov, *Bull. Exp. Biol. Med.*, **151**, No. 6, 664-666 (2011).
2. T. L. Zefirov, L. I. Khisamieva, N. I. Ziyatdinova, and A. L. Zefirov, *Bull. Exp. Biol. Med.*, **158**, No. 4, 410-412 (2015).
3. M. Brede, G. Nagy, M. Philipp, and J. B. Sorensen, *Mol. Endocrinol.*, **17**, No. 8, 1640-1646 (2003).
4. M. Brede, F. Wiesmann, R. Jahns, et al., *Circulation*, **106**, No. 19, 2491-2496 (2002).
5. O. E. Brodde and K. Leineweber, *Eur. J. Pharmacol.*, **500**, Nos. 1-3, 167-176 (2004).
6. B. Civantos Calzada and A. Alexandre de Artinano, *Pharmacol. Res.*, **44**, No. 3, 195-208 (2001).
7. R. El-Ayoubi, A. Menaouar, J. Gutkowska, and S. Mukaddam-Daher, *J. Pharmacol. Exp. Ther.*, **310**, No. 2, 446-451 (2004).
8. K. Gyires, Z. S. Zadori, T. Torok, and P. Matyus, *Neurochem. Int.*, **55**, No. 7, 447-453 (2009).
9. K. Leineweber, *Ann. Med.*, **36**, Suppl. 1, 64-69 (2004).
10. A. Lympertopoulos, G. Rengo, and W. J. Koch, *Trends Mol. Med.*, **13**, No. 12, 503-511 (2007).
11. A. V. Maltsev, Y. M. Kokoz, E. V. Evdokimovskii, et al., *J. Mol. Cell. Cardiol.*, **68**, 66-74 (2014).
12. M. Philipp, M. Brede, and L. Hein, *Am. J. Physiol. Regul. Integr. Comp. Physiol.*, **283**, No. 2, R287-R295 (2002).
13. M. Philipp and L. Hein, *Pharmacol. Ther.*, **101**, No. 1, 65-74 (2004).
14. A. Snipir, P. Heinonen, T. P. Tuomainen, et al., *J. Am. Coll. Cardiol.*, **37**, No. 6, 1516-1522 (2001).
15. T. L. Zefirov, N. I. Ziyatdinova, L. I. Khisamieva, and A. L. Zefirov, *Bull. Exp. Biol. Med.*, **157**, No. 2, 194-197 (2014).